Synairgen (LON:SNG) Shares Down 0.2% – Should You Sell?

Synairgen plc (LON:SNG)’s share price fell 0.2% during trading on Monday . The stock traded as low as GBX 1.81 ($0.02) and last traded at GBX 2 ($0.02). 478,281 shares traded hands during trading, a decline of 82% from the average session volume of 2,614,922 shares. The stock had previously closed at GBX 2 ($0.02).

Synairgen Trading Up 6.4 %

The company has a debt-to-equity ratio of 0.09, a current ratio of 6.77 and a quick ratio of 6.35. The company has a market capitalization of £3.69 million, a P/E ratio of -61.00 and a beta of -2.23. The firm has a fifty day moving average price of GBX 3.51 and a 200-day moving average price of GBX 3.91.

About Synairgen

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).